MPM Oncology Impact Management »

Adaptimmune Therapeutics shares owned by MPM Oncology Impact Management

Quarter-by-quarter ownership of Adaptimmune Therapeutics (ADAP) shares owned by MPM Oncology Impact Management from 13F filings

Historical chart of MPM Oncology Impact Management investment in Adaptimmune Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Adaptimmune Therapeutics held by MPM Oncology Impact Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Adaptimmune Therapeutics by MPM Oncology Impact Management

Quarter filed Position value Share count Share price at filing
2024-06-30 $5.0M 5.1M 0.98
2024-03-31 $8.1M 5.1M 1.58
2023-09-30 $4.0M 5.1M 0.78
2023-06-30 $4.7M 5.1M 0.93

More positions owned by MPM Oncology Impact Management

Cullinan Therapeutics Common (CGEM)
Insmed Incorporated Common (INSM)
Olema Pharmaceuticals Common (OLMA)
iTeos Therapeutics Common (ITOS)
Crinetics Pharmaceuticals Common (CRNX)
Madrigal Pharmaceuticals Common (MDGL)
Iovance Biotherapeutics Common (IOVA)
Natera Common (NTRA)
Mirum Pharmaceuticals Common (MIRM)
Ultragenyx Pharmaceutical Common (RARE)
Moonlake Immunotherapeutics Class A Ord (MLTX)
Guardant Health Common (GH)
Disc Medicine Common (IRON)
Alkermes Common (ALKS)
Edgewise Therapeutics Common (EWTX)

View all positions for MPM Oncology Impact Management

Top funds holding Adaptimmune Therapeutics

EcoR1 Capital
NEA Management Company
Baillie Gifford & Co
Long Focus Capital Management
Partner Fund Management
MPM Asset Management
MPM Oncology Impact Management
Bank of America Corporation
Rock Springs Capital Management
Baker Bros. Advisors
Tang Capital Management
Renaissance Technologies
Jpmorgan Chase & Co
Millennium Management
Redmile Group

View all funds holding Adaptimmune Therapeutics